Home / Top News / Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina
Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina
ROSELAND, N.J., March 02, 2021 (GLOBE NEWSWIRE)
Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has begun selling CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC). The MUSC University Medical Center is a nationally recognized and leading health sciences university, recently ranked as the number one hospital in South Carolina. MUSC Health owns and operates eight hospitals and provides patient care throughout the state of South Carolina.
E-Mail
IMAGE: 3D computer-generated image of a cluster of rod-shaped, drug-resistant Mycobacterium tuberculosis bacteria, the pathogen responsible for causing the disease tuberculosis. Image courtesy of the CDC. view more
Credit: Centers for Disease Control and Prevention
Susan Dorman, M.D., an infectious disease physician at the Medical University of South Carolina (MUSC), was recently awarded a 10-year, $9.9 million contract by the Centers for Disease Control and Prevention to run trials for the Tuberculosis Trials Consortium (TBTC). The TBTC is a collaboration of researchers whose goal is to improve the diagnosis, management and prevention of tuberculosis (TB) around the world. Dorman, who has dedicated her career to studying the disease, serves as a TB medical consultant for the South Carolina Department of Health and Environmental Control and leads research efforts to improve TB treatment and prevention.
E-Mail
IMAGE: Dr. Xue-Zhong Yu and his research team s findings suggest there could be a new way to protect bone marrow transplant recipients from graft-versus-host disease. view more
Credit: MUSC Hollings Cancer Center
MUSC Hollings Cancer Center researcher Yongxia Wu, Ph.D., identified a new target molecule in the fight against graft-versus-host disease (GVHD). Bone marrow transplant, a treatment for certain blood cancers, is accompanied by potentially life-threatening GVHD in nearly 50% of patients. A January 2021 paper published in
Cellular and Molecular Immunology revealed that activating a molecule called STING may be a new approach to reduce GVHD.
Xue-Zhong Yu, M.D., professor in the Department of Microbiology and Immunology, focuses on understanding the intricate immune mechanisms that regulate GVHD development and anti-tumor activity.